Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Sinha R, Doval DC, Hussain S, Kumar K, Singh S, Basir SF, Bharadwaj M. Lifestyle and sporadic colorectal cancer in India. Asian Pac J Cancer Prev. 2015;16(17):7683–8.

Article  PubMed  Google Scholar 

Markowitz SD, Bertagnolli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Müller MF, Ibrahim AE, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469:125–34.

Article  PubMed  PubMed Central  Google Scholar 

Guinney J, Dienstmann R, Wang X, de Reyniès A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Akiyama M, Matsuda Y, Arai T, Saeki H. PD-L1 expression in malignant melanomas of the skin and gastrointestinal tract. Oncol Lett. 2020;19(3):2481–8.

CAS  PubMed  PubMed Central  Google Scholar 

Yuan C, Liu Z, Yu Q, Wang X, Bian M, Yu Z, Yu J. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci Rep. 2019;9(1):14356.

Article  PubMed  PubMed Central  Google Scholar 

Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel-Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci. 2019;20(4):824.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu X, Choi MG, Kim K, Kim KM, Kim ST, Park SH, Cristescu R, Peter S, Lee J. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216(4): 152881.

Article  CAS  PubMed  Google Scholar 

Srivastava P, Husain N, Shukla S, Chauhan S, Pandey A, Masood S. PD-L1 Expression in colorectal carcinoma and its correlation with clinicopathological parameters, microsatellite instability and BRAF mutation. Indian J Pathol Microbiol. 2021;64(3):490–6.

Article  PubMed  Google Scholar 

Shan T, Chen S, Wu T, Yang Y, Li S, Chen X. PD-L1 expression in colon cancer and its relationship with clinical prognosis. Int J Clin Exp Pathol. 2019;12(5):1764–9 Int J Clin Exp Pathol. 2022;15(3):155–156.

CAS  PubMed  PubMed Central  Google Scholar 

Gupta M, Manjari M, Kaur H. PD-L1 Expression in colorectal carcinoma: immunohistochemical study. Annals of Pathology and Laboratory Medicine. 2020;7:A275-281.

Article  Google Scholar 

Salemme V, Centonze G, Cavallo F, Defilippi P, Conti L. The crosstalk between tumor cells and the immune microenvironment in breast cancer: implications for immunotherapy. Front Oncol. 2021;11: 610303.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Soldevilla B, Carretero-Puche C, Gomez-Lopez G, Al-Shahrour F, Riesco MC, Gil-Calderon B, et al. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications. Eur J Cancer. 2019;123:118–29.

Article  CAS  PubMed  Google Scholar 

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18(1):1–7.

Article  CAS  Google Scholar 

Scognamiglio T, Chen YT. Beyond the percentages of PD-L1-positive tumor cells: induced versus constitutive PD-L1 expression in primary and metastatic head and neck squamous cell carcinoma. Head Neck Pathol. 2018;12(2):221–9.

Article  PubMed  Google Scholar 

Lin G, Fan X, Zhu W, Huang C, Zhuang W, Xu H, et al. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. Oncotarget. 2017;8(48):83986.

Article  PubMed  PubMed Central  Google Scholar 

Mastracci L, Grillo F, Parente P, Gullo I, Campora M, Angerilli V, et al. PD-L1 evaluation in the gastrointestinal tract: from biological rationale to its clinical application. Pathologica. 2022;114(5):352–64.

Article  PubMed  PubMed Central  Google Scholar 

Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol. 2007;60:1112–6.

Article  PubMed  Google Scholar 

Agrawal L, Engel KB, Greytak SR, Moore HM. Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy. Semin Cancer Biol. 2018;52(Pt 2):26–38.

Article  CAS  PubMed  Google Scholar 

Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG, et al. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother. 2017;40(9):323–33.

Article  CAS  PubMed  Google Scholar 

Bai J, Chen H, Bai X. Relationship between microsatellite status and immune microenvironment of colorectal cancer and its application to diagnosis and treatment. J Clin Lab Anal. 2021;35(6): e23810.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng M, Li SH, Fu X, Yan XP, Chen J, Qiu YD, Guo RP. Relationship between PD-L1 expression, CD8+ T-cell infiltration and prognosis in intrahepatic cholangiocarcinoma patients. Cancer Cell Int. 2021;21(1):371.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Que Y, Xiao W, Guan YX, Liang Y, Yan SM, Chen HY, et al. PD-L1 expression is associated with FOXP3+ regulatory T-cell infiltration of soft tissue sarcoma and poor patient prognosis. J Cancer. 2017;8(11):2018–25.

Article  PubMed  PubMed Central  Google Scholar 

Sumitomo R, Hirai T, Fujita M, Murakami H, Otake Y, Huang CL. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer. 2019;136:136–44.

Article  PubMed  Google Scholar 

Arias-Pulido H, Cimino-Mathews A, Chaher N, Qualls C, Joste N, Colpaert C, Marotti JD, Foisey M, Prossnitz ER, Emens LA, Fiering S. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome. Breast Cancer Res Treat. 2018;171(2):273–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guo G, Wang Y, Zhou Y, Quan Q, Zhang Y, Wang H, Zhang B, Xia L. Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes. J Immunother Cancer. 2019;7(1):179.

Article  PubMed  PubMed Central  Google Scholar 

Takasu C, Nishi M, Yoshikawa K, Tokunaga T, Kashihara H, Yoshimoto T, Shimada M. Impact of sidedness of colorectal cancer on tumor immunity. PLoS ONE. 2020;15(10): e0240408.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Valentini AM, Di Pinto F, Cariola F, Guerra V, Giannelli G, Caruso ML, Pirrelli M. PD-L1 expression in colorectal cancer defines three subsets of tumor immune microenvironments. Oncotarget. 2018;9(9):8584–96.

Article  PubMed  PubMed Central  Google Scholar 

Chen Y, Liu Q, Chen Z, Wang Y, Yang W, Hu Y, Han W, Zeng H, Ma H, Dai J, Zhang H. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):193.

Article  PubMed  PubMed Central  Google Scholar